Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Treatment with selinexor, bortezomib, and dexamethasone demonstrated an increase in overall response rate and progression-free survival in patients with multiple myeloma and high cytogenetic risk despite a dosing schedule that utilized 40% less bortezomib and 25% less dexamethasone during the first 24 weeks of treatment.
Patients with refractory large B-cell lymphoma experienced long-term disease control with rapid responses and robust CAR T-cell expansion with the CAR T-cell therapy axicabtagene ciloleucel.
Patients with intermediate- or high-risk myelofibrosis in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials experienced improved overall survival and sustained efficacy outcomes with momelitinib.
In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.
Higher doses of telomerase inhibitor imetelstat demonstrated better overall survival, spleen response, and symptom response in patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors in the phase 2 IMbark study.
Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.
A post-hoc analysis of the SADAL trial showed there was clinical benefit with selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma regardless of age.
Patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy had significantly prolonged overall survival and relapse-free survival with azacitidine.
The oral, selective menin inhibtor KO-539 showed activity in preliminary findings of the ongoing first-in-human KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia.
The phase 3 REACH3 trial of ruxolitinib in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids demonstrated significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement compared with best available therapy.
Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.
Ulka Vaishampayan, MD, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.
A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.
Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.
In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.
Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.
In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.
Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.
Neoadjuvant treatment with the PD-1 inhibitor nivolumab demonstrated tolerability in patients with nonmetastatic high-risk clear cell renal cell carcinoma in a phase 1 trial.
The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.
Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.
Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.
In an interview with Targeted Oncology during the Association for Molecular Pathology 2020 Annual Meeting, Rachel Sparks, MD, discussed the findings observed in hematologic malignancies with the use of a new RNA-based NGS assay.
Victor Velculescu, MD, PhD, discusses the key takeaways regarding the use of liquid biopsy to detect cancer and a new cfDNA approach to detect cancer at earlier stages.
In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.
Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.